Bioradiations Staff
 Kenneth Oh |
Kelly King |
Brad VanderWielen |
Candice Cox |
| Presented by: Kenneth Oh, PhD, Collaborations, Applications, and New Technology Senior Global Manager Kelly King, PhD, Field Application Specialist II Brad VanderWielen, PhD, Field Application Specialist II Candice Cox, Global Marketing Manager, Immunoassays |
|
|
Date: February 9, 2021 | |
Several publications have reported the varying duration of acquired immunity to SARS-CoV-2. We will review these reports and discuss numerous factors that contribute to the longevity and duration of such immunity by discussing some of the underlying mechanisms of the adaptive immune response, including lymphocyte activity, cytokine and chemokine activity, as well as the effects of preexisting conditions and immune history. Additionally, we will investigate the relationship between symptom severity and the longevity of acquired immunity.
You will learn about:
- SARS‑CoV‑2 virion and ACE2 binding
- Initiation of the adaptive response
- T‑ and B‑lymphocyte maturity
- B‑lymphocyte conversion to memory and plasma cells
- Factors that affect the duration of acquired immunity